Advertisement

 

 

HBV, HCV Coinfection Ups Non-Hodgkin Risk in ART-Treated HIV

HBV, HCV Coinfection Ups Non-Hodgkin Risk in ART-Treated HIV
Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

TUESDAY, Oct. 18, 2016 (HealthDay News) — Chronic coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is associated with non-Hodgkin’s lymphoma (NHL) among patients with HIV receiving antiretroviral treatment (ART), according to a study published online Oct. 18 in the Annals of Internal Medicine.

Qing Wang, Ph.D., from the University Hospital Basel in Switzerland, and colleagues conducted a cohort study to examine whether chronic HBV and HCV infection correlate with increased incidence of NHL in HIV-infected patients using data from 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe. Data were included for 52,479 treatment-naive patients (2.6 and 14.3 percent with chronic HBV infection and HCV infection, respectively); 77 percent of these patients started ART.

The researchers found that 252 treatment-naive and 310 treated patients developed NHL (incidence rates of 219 and 168 per 100,000 person-years, respectively). The hazard ratios for NHL were 1.33 (95 percent confidence interval [CI], 0.69 to 2.56) for HBV infection and 0.67 (95 percent CI, 0.40 to 1.12) for HCV infection in treatment-naive patients, and 1.74 (95 percent CI, 1.08 to 2.82) and 1.73 (95 percent CI, 1.21 to 2.46), respectively, for treated patients.

“In HIV-infected patients receiving ART, chronic coinfection with HBV and HCV is associated with an increased risk for NHL,” the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.
healthday

Submit a Comment

Your email address will not be published. Required fields are marked *

1 × 4 =

[ HIDE/SHOW ]